CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 54 enrolled
Drug / intervention
Temsirolimusdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01827943
NCT01827943Phase 2Completed
CompareCT.gov

Phase II Trial, Evaluating Efficacy of Temsirolimus (Torisel ®) in Second Line Therapy for Patients With Advanced Bladder Cancer

Institut Bergonié·interventional·Posted Apr 10, 2013·Updated May 6, 2021

In Brief

A Phase 2 clinical trial evaluating Temsirolimus for Relapsed Bladder Cancer. Completed, enrolled 54 participants across 9 sites.

Detailed Summary

In the absence of standard treatment in this indication, this test evaluates a new drug type targeted therapy in this indication, evaluating its efficacy in terms of tumor response and survival.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRelapsed Bladder Cancer
CountriesFrance
CollaboratorsWyeth is now a wholly owned subsidiary of Pfizer

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 10, 2013
Enrollment StartJun 1, 2009
Primary CompletionDec 1, 2014
Study CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 13.2 years ago

Interventions

Temsirolimusdrug

Temsirolimus